Monoclonal antibodies combined with adenovirus-vectored interferon significantly extend the treatment window in Ebola virus-infected guinea pigs.
J Virol
; 87(13): 7754-7, 2013 Jul.
Article
em En
| MEDLINE
| ID: mdl-23616649
ABSTRACT
Monoclonal antibodies (MAbs) are currently a promising treatment strategy against Ebola virus infection. This study combined MAbs with an adenovirus-vectored interferon (DEF201) to evaluate the efficacy in guinea pigs and extend the treatment window obtained with MAbs alone. Initiating the combination therapy at 3 days postinfection (d.p.i.) provided 100% survival, a significant improvement over survival with either treatment alone. The administration of DEF201 within 2 d.p.i. permits later MAb use, with protective efficacy observed up to 8 d.p.i.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Interferon-alfa
/
Doença pelo Vírus Ebola
/
Ebolavirus
/
Anticorpos Monoclonais
Limite:
Animals
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article